Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.155

+3.1%

Nov 24 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: JMarcus	6/19/2007 10:52:07 AM
	of 3576

Here's Adam Feuerstein's recap of last week's action: A painful lesson learned in Geron (GERN) this week: If investors insist on owning this highly speculative and relatively expensive biotech stock, please buy it after the company disappoints with either lackluster clinical data or some delay/setback in its pipeline. The thing to remember about Geron is that it is a stock pumper's dream. Some headline about stem cells hits the tape, the CEO makes yet another bullish comment or an article or two is published about the greatness of Geron's science -- the result: Momentum investors and daytraders get to sell overpriced shares to gullible buyers who think this time, finally, is Geron's breakthrough moment. Except, it's not. This week was so typical. In May, people got all excited about data from the company's telomerase-inhibitor cancer drug, GRN163L. The stock was bid up in anticipation. But when the data were finally presented this week, it disappoints. The stock falls. It's happened before, it will again.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next